Regn stock price saw intraday highs of $942

REGN stock price saw intraday highs of $942.66 after news of expanded phase 3 data for its Dupixent drug. Analysts predict such clinical success could add $1.5B in annual revenue within the next two fiscal years. REGN stock is a Strong Buy, according to analysts, with 17 Buys, two Holds, and one Sell assigned in the past three months. The average REGN stock price target of $1,074.22 implies 4.5% upside potential. Our team is working diligently to resolve the issue. Thank you for your patience and understanding. With REGN stock price hovering at $931.77, sentiment is mildly bullish ahead of earnings. Data from Refinitiv shows consensus EPS forecasts slightly higher than a quarter ago, implying analysts expect margin expansion from higher-priced new treatments.